PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020

Category: .

PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020

INDICATIONS AND USAGE
PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for:
• Use in combination with chemotherapy as:
o neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
o adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence
• Use in combination with docetaxel for treatment of patients with HER2­ positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DOSAGE FORMS & STRENGTHS
Injection:
• 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial.
• 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL (60 mg, 60 mg, and 2,000 units/mL) of solution in a single-dose vial.
Manufactured By: Genentech
Prescribing Information URL: Click Here

Access to PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Pertuzumab, trastuzumab, and hyaluronidase-zzxf is approved to be given with docetaxel or other chemotherapy to treat:
Breast cancer that is HER2 positive. It is used:
• As neoadjuvant therapy (to shrink the tumor before surgery) in adults with locally advanced, inflammatory, or early-stage breast cancer. It is given with chemotherapy.
• As adjuvant therapy in adults with early-stage breast cancer who have a high risk that their cancer will recur (come back). It is given with chemotherapy.
• In adults with metastatic breast cancer that has not been treated with anti-HER2 therapy or chemotherapy. It is given with docetaxel.
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed-dose combination of pertuzumab and trastuzumab that is given as a subcutaneous injection. It can be given in less time than pertuzumab or trastuzumab, which are given as infusions. For more information about pertuzumab and trastuzumab that may apply to pertuzumab, trastuzumab, and hyaluronidase-zzxf, see the Drug Information Summaries for Pertuzumab and Trastuzumab.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.